https://orcid.org/0000-0002-4568-9783
Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Cedric J Rutland, Onyinye I Iweala, Kyle Anders, Jinnie Ko, Parul Mital, Sachin Gupta & Arjun Mohan. (2023) Antitussive Use in Patients with Inadequately Controlled Moderate-to-Severe Asthma: A Post Hoc Analysis of the Omalizumab EXTRA Trial. Journal of Asthma and Allergy 16, pages 661-665.
Read now
Read now
Deniz Tugay, Mehmet Top, Ömür Aydin, Sevim Bavbek, Ebru Damadoğlu, Ferda Öner Erkekol, Ilkay Koca Kalkan, A. Fuat Kalyoncu, Gül Karakaya, I. Kivilcim Oğuzülgen, Haluk Türktaş & Ivo Abraham. (2023) Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey. Journal of Medical Economics 26:1, pages 720-730.
Read now
Read now
Juliana S. Nakamuta, Ana Lia Pradella Puglia, Paula Meireles, Daniela Cavalet Blanco, Marina Andrade Lima, Marina Gabriela Birck, Marion Coting Braga, Renato Watanabe de Oliveira, Guilherme Silva Julian & Francisco Jose Forestiero. (2023) Asthma control in Brazil: a systematic review. Journal of Asthma 60:5, pages 868-880.
Read now
Read now
Maria De Filippo, Martina Votto, Amelia Licari, Fabio Pagella, Marco Benazzo, Giorgio Ciprandi & Gian Luigi Marseglia. (2021) Novel therapeutic approaches targeting endotypes of severe airway disease. Expert Review of Respiratory Medicine 15:10, pages 1303-1316.
Read now
Read now
Sinem Ornek & Emek Kocaturk. (2021) A patient-oriented approach to long-term use of omalizumab in chronic spontaneous urticaria. Cutaneous and Ocular Toxicology 40:4, pages 305-311.
Read now
Read now
Kenneth M. Faulkner, Karen MacDonald, Ivo Abraham, Abdulaziz Alhossan & Christopher S. Lee. (2021) ‘Real-world’ effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert Review of Clinical Immunology 17:1, pages 73-83.
Read now
Read now
Aleksandra Kucharczyk, Ewa Więsik-Szewczyk, Anna Poznańska & Karina Jahnz-Różyk. (2020) Clinical Determinants of Successful Omalizumab Therapy in Severe Allergic Asthma Patients: 4-Year-Long, Real-Life Observation. Journal of Asthma and Allergy 13, pages 659-668.
Read now
Read now
Sheila Cabrejos, Ana Moreira, Andreina Ramirez, Santiago Quirce, Gregorio Soto Campos, Ignacio Dávila & Paloma Campo. (2020) FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma. Journal of Asthma and Allergy 13, pages 159-166.
Read now
Read now
Articles from other publishers (46)
V. V. Naumova, E. K. Beltyukov, D. V. Kiseleva, A. A. Shtanova & D. A. Stepina. (2023) Omalizumab: a quarter of a century in the fight against T2-inflammatory diseases of upper and lower respiratory tract. Meditsinskiy sovet = Medical Council:20, pages 68-83.
Crossref
Crossref
Linda Rogers, Milos Jesenak, Leif Bjermer, Nicola A. Hanania, Sven F. Seys & Zuzana Diamant. (2023) Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient. Respiratory Medicine 218, pages 107414.
Crossref
Crossref
Julio Delgado, Ana Navarro, Francisco Javier Álvarez-Gutiérrez, Carolina Cisneros & Javier Domínguez-Ortega. (2023) Necesidades no cubiertas en asma alérgica grave. Open Respiratory Archives 5:4, pages 100282.
Crossref
Crossref
Hanna K. Mandl, Jessa E. Miller & Daniel M. Beswick. (2023) Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps. Otolaryngologic Clinics of North America.
Crossref
Crossref
Raja Dhar, Chin Kook Rhee, Diahn‐Warng Perng, Koichi Fukunaga, Mary Sau‐Man Ip, Siwasak Juthong, Mariko Siyue Koh, Jing Li, Shubham Sharma & Wiwien Heru Wiyono. (2023) The burden of systemic corticosteroid use in asthma management in Asia. Respirology 28:8, pages 744-757.
Crossref
Crossref
Francesco Menzella, Jocelyne Just, Inessa Schwab Sauerbeck, Claudia Mailaender, Fabiana Saccheri, Celine Thonnelier, Xavier Jaumont & Laurence Mala. (2023) Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL. World Allergy Organization Journal 16:6, pages 100787.
Crossref
Crossref
Adel H. Mansur, Sherif Gonem, Thomas Brown, Hassan Burhan, Rekha Chaudhuri, James W. Dodd, Thomas Pantin, Robin Gore, David Jackson, Andrew Menzies‐Gow, Mitesh Patel, Ian Pavord, Paul Pfeffer, Salman Siddiqui, John Busby & Liam G. Heaney. (2022)
Biologic therapy practices in severe asthma; outcomes from the
UK
Severe Asthma Registry and survey of specialist opinion
. Clinical & Experimental Allergy 53:2, pages 173-185.
Crossref
Crossref
Lorenzo Salvati, Francesco Liotta, Francesco Annunziato & Lorenzo Cosmi. (2022) Therapeutical Targets in Allergic Inflammation. Biomedicines 10:11, pages 2874.
Crossref
Crossref
Geoffrey Chupp & Michael E. Wechsler. (2022) Biologic medications in asthma. Annals of Allergy, Asthma & Immunology 129:2, pages 138-139.
Crossref
Crossref
Jesús López-Tiro, Angelica Contreras-Contreras, M. Eunice Rodríguez-Arellano & Paula Costa-Urrutia. (2022) Economic burden of severe asthma treatment: A real-life study. World Allergy Organization Journal 15:7, pages 100662.
Crossref
Crossref
D. S. Kulichenko, K. S. Pavlova, O. M. Kurbacheva & N. I. Ilina. (2022) Personalized targeted therapy of moderate and severe atopic asthma in Russia. Meditsinskiy sovet = Medical Council:4, pages 15-23.
Crossref
Crossref
Marek Lommatzsch, Guy G Brusselle, G Walter Canonica, David J Jackson, Parameswaran Nair, Roland Buhl & Johann Christian Virchow. (2022) Disease-modifying anti-asthmatic drugs. The Lancet 399:10335, pages 1664-1668.
Crossref
Crossref
Joice Mara de Oliveira1,2Fatima Mitsie Chibana Soares3Fabio Pitta2Karina Couto Furlanetto1,2. (2022) Adults with asthma treated with add-on omalizumab report less limitation in activities of daily living. Jornal Brasileiro de Pneumologia, pages e20210321.
Crossref
Crossref
Jonathan Corren, Jared Silver, Nestor A. Molfino, Michael Bogart, Elizabeth Packnett, Donna McMorrow, Juan Wu & Beth Hahn. (2022) A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumab. Annals of Allergy, Asthma & Immunology 128:2, pages 184-192.e1.
Crossref
Crossref
Ataru Igarashi, Harneet Kaur, Abhay Choubey, Akshay Popli, Madhusubramanian Muthukumar, Hajime Yoshisue, Minako Funakubo & Ken Ohta. (2022) Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence. Value in Health Regional Issues 27, pages 41-48.
Crossref
Crossref
Regina Maria de Carvalho-Pinto1, José Eduardo Delfini Cançado2, Marcia Margaret Menezes Pizzichini3, Jussara Fiterman4, Adalberto Sperb Rubin5,6, Alcindo Cerci Neto7,8, Álvaro Augusto Cruz9,10Ana Luisa Godoy Fernandes11, Ana Maria Silva Araujo12, Daniela Cavalet Blanco13, Gediel Cordeiro Junior14,15, Lilian Serrasqueiro Ballini Caetano11, Marcelo Fouad Rabahi16, Marcelo Bezerra de Menezes17, Maria Alenita de Oliveira18, Marina Andrade Lima19 & Paulo Márcio Pitrez20. (2021) 2021 Brazilian Thoracic Association recommendations for the management of severe asthma. Jornal Brasileiro de Pneumologia, pages e20210273.
Crossref
Crossref
Abdulrahman Alzahrani, Jameel Hakeem, Michael Biddle, Fahad Alhadian, Aamir Hussain, Latifa Khalfaoui, Katy M. Roach, Omar Tliba, Peter Bradding & Yassine Amrani. (2021) Human Lung Mast Cells Impair Corticosteroid Responsiveness in Human Airway Smooth Muscle Cells. Frontiers in Allergy 2.
Crossref
Crossref
Joanne E. Kavanagh, Andrew P. Hearn & David J. Jackson. (2022) A pragmatic guide to choosing biologic therapies in severe asthma. Breathe 17:4, pages 210144.
Crossref
Crossref
Xue-Jun Kong, Cullen Clairmont & Bryan Wang. (2021) Case Report: Off-Label Use of Omalizumab in a 6-Year-Old Boy With ASD Ameliorated Severe Allergic Rhinitis and Subsequently Improved Behavioral Symptoms. Frontiers in Pediatrics 9.
Crossref
Crossref
Katerina Antoniou, Maria Bolaki, Konstantinos Karagiannis, Athina Trachalaki, Despo Ierodiakonou, Vagia Stamatopoulou, Charito Chatzinikolaou, Semeli Mastrodimou, Evangelia Stamataki, George Pitsidianakis, Irini Lambiri, Ioanna Mitrouska, Demetrios Spandidos & Nikolaos Tzanakis. (2021) Real‑life Cretan asthma registry focused on severe asthma: On behalf of ‘The Cretan registry of the use of Biologics in Severe Asthma’. Experimental and Therapeutic Medicine 22:5.
Crossref
Crossref
Min Zhang, Meiling Jin, Xin Zhou, Jiangtao Lin, Xiansheng Liu, Chuntao Liu, Mao Huang, Wen Wang, Liang Chen, Yijiang Huang, Jing Li, Qingling Zhang, Huahao Shen, Yali Yu, Wei Tang, Jianying Zhou, Hongju Liu, Liang Dong, Yan Hu, Hua Wu, Yanhong Li, Weidong Song, Ming Ouyang, Xiaoling Yuan, Tao Wang & Shengdao Xiong. (2021) Effectiveness of omalizumab in patients with severe allergic asthma: A retrospective study in China. Respiratory Medicine 186, pages 106522.
Crossref
Crossref
Wei Chern Gavin Fong, Adnan Azim, Deborah Knight, Heena Mistry, Anna Freeman, Mae Felongco, Aref Kyyaly, Matthew Harvey, Patrick Dennison, Hongmei Zhang, Peter Howarth, Syed Hasan Arshad & Ramesh J. Kurukulaaratchy. (2021) Real‐world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes. Clinical & Experimental Allergy 51:8, pages 1019-1032.
Crossref
Crossref
Weily Soong, Bongin Yoo, Hooman Pazwash, Cecile T.J. Holweg & Thomas B. Casale. (2021) Omalizumab response in patients with asthma by number and type of allergen. Annals of Allergy, Asthma & Immunology 127:2, pages 223-231.
Crossref
Crossref
Jean Bousquet, Marc Humbert, Peter G. Gibson, Konstantinos Kostikas, Xavier Jaumont, Pascal Pfister & Francis Nissen. (2021) Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. The Journal of Allergy and Clinical Immunology: In Practice 9:7, pages 2702-2714.
Crossref
Crossref
Chiao-Juno Chiu & Miao-Tzu Huang. (2021) Asthma in the Precision Medicine Era: Biologics and Probiotics. International Journal of Molecular Sciences 22:9, pages 4528.
Crossref
Crossref
Lynda Jarrell. (2021) Eosinophilic asthma and the role of monoclonal antibodies. The Nurse Practitioner 46:4, pages 21-27.
Crossref
Crossref
Wei-Chang Huang, Pin-Kuei Fu, Ming-Cheng Chan, Chun-Shih Chin, Wen-Nan Huang, Kuo-Lung Lai, Jiun-Long Wang, Wei-Ting Hung, Yi-Da Wu, Chia-Wei Hsieh, Ming-Feng Wu, Yi-Hsing Chen & Jeng-Yuan Hsu. (2021) The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment. Journal of Clinical Medicine 10:4, pages 707.
Crossref
Crossref
Shih-Lung Cheng. (2021) Immunologic Pathophysiology and Airway Remodeling Mechanism in Severe Asthma: Focused on IgE-Mediated Pathways. Diagnostics 11:1, pages 83.
Crossref
Crossref
Lu Chen & Yanping Chen. (2021) Effects of omalizumab in children with asthma. Medicine 100:22, pages e26155.
Crossref
Crossref
Abdulrahman Alzahrani, Aamir Hussain, Fahad Alhadian, Jameel Hakeem, Sana Douaoui, Omar Tliba, Peter Bradding & Yassine Amrani. 2021. Lung Inflammation in Health and Disease, Volume I. Lung Inflammation in Health and Disease, Volume I
1
12
.
Jordis Trischler, Ivan Bottoli, Reinhold Janocha, Christoph Heusser, Xavier Jaumont, Phil Lowe, Aurelie Gautier, Abhijit Pethe, Ralph Woessner, Hans‐Günter Zerwes & Stefan Zielen. (2021) Ligelizumab treatment for severe asthma: learnings from the clinical development programme. Clinical & Translational Immunology 10:3.
Crossref
Crossref
N. M. Nenasheva, A. V. Averyanov, N. I. Il'ina, S. N. Avdeev, G. L. Osipova, T. V. Rubanik, V. N. Zorin, A. O. Molotkov, N. A. Kuzubova, N. E. Kostina, L. M. Kudelya & D. V. Petrov. (2020) Comparative Study cf Biosimilar Genolar® Clinical Efficacy оп the Randomized Phase III Study Results. PULMONOLOGIYA 30:6, pages 782-796.
Crossref
Crossref
Jessica Purizaca-Bazán & José Antonio Ortega-Martell. (2020) Bloqueo de inmunoglobulina E en el asma grave. Revista Alergia México 67.
Crossref
Crossref
Giovanni Rolla, Enrico Heffler, Stefano Pizzimenti, Alain Michils & Andrei Malinovschi. (2020) An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma. Current Medicinal Chemistry 27:42, pages 7159-7167.
Crossref
Crossref
Marco Caminati, Diego Bagnasco, Lanny J. Rosenwasser, Andrea Vianello & Gianenrico Senna. (2020) Biologics for the Treatments of Allergic Conditions. Immunology and Allergy Clinics of North America 40:4, pages 549-564.
Crossref
Crossref
Koichiro Asano, Kazuya Sumi, Hajime Yoshisue, Noriko Nakamura, Makoto Nagasaki, Takayoshi Sasajima & Hisako Matsumoto. (2020) Real-life safety and efficacy of omalizumab in Japanese patients with severe allergic asthma who were subjected to dosing table revision or expansion: A post-marketing surveillance. Pulmonary Pharmacology & Therapeutics 64, pages 101950.
Crossref
Crossref
Florence Schleich, Sophie Graff, Haleh Nekoee, Catherine Moermans, Monique Henket, Carole Sanchez, Virginie Paulus, Françoise Guissard, Anne‐Françoise Donneau & Renaud Louis. (2020) Real‐world experience with mepolizumab: Does it deliver what it has promised?. Clinical & Experimental Allergy 50:6, pages 687-695.
Crossref
Crossref
Ebymar Arismendi & César Picado Vallés. (2020) Papel de los biomarcadores en el asma grave no controlada en la actualidad. Archivos de Bronconeumología 56:6, pages 347-348.
Crossref
Crossref
Ebymar Arismendi & César Picado Vallés. (2020) Current Role of Biomarkers in Severe Uncontrolled Asthma. Archivos de Bronconeumología (English Edition) 56:6, pages 347-348.
Crossref
Crossref
Ioana Agache, Claudio Rocha, Jessica Beltran, Yang Song, Margarita Posso, Ivan Solà, Pablo Alonso‐Coello, Cezmi Akdis, Mubeccel Akdis, Giorgio W. Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Stefano Del Giacco, Thomas Eiwegger, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Mika Mäkelä, Irene Hernández Martín, Parameswaran Nair, Liam O'Mahony, Nikolaos G. Papadopoulos, Alberto Papi, Hae‐Sim Park, Luis Pérez de Llano, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Jurgen Schwarze, Carlos Canelo‐Aybar, Oscar Palomares & Marek Jutel. (2020) Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy 75:5, pages 1043-1057.
Crossref
Crossref
Reiko Ito. (2020) Latest Information on the Diagnosis and Treatment of Adult Asthma成人気管支喘息の診断・治療の最新情報. Journal of Nihon University Medical Association 79:2, pages 77-80.
Crossref
Crossref
Steve Chaplin. (2020) Monoclonal antibodies for the treatment of severe asthma. Prescriber 31:3, pages 23-28.
Crossref
Crossref
Diego Bagnasco, Marco Caminati & Giovanni Passalacqua. (2020) Biologicals for severe asthma: what we can learn from real-life experiences?. Current Opinion in Allergy & Clinical Immunology 20:1, pages 64-70.
Crossref
Crossref
Marcia Margaret Menezes Pizzichini, Regina Maria de Carvalho-Pinto, José Eduardo Delfini Cançado, Adalberto Sperb Rubin,, Alcindo Cerci Neto, Alexandre Pinto Cardoso, Alvaro Augusto Cruz, Ana Luisa Godoy Fernandes, Daniella Cavalet Blanco, Elcio Oliveira Vianna, Gediel Cordeiro Junior, José Angelo Rizzo, Leandro Genehr Fritscher, Lilian Serrasqueiro Ballini Caetano, Luiz Fernando Ferreira Pereira, Marcelo Fouad Rabahi, Maria Alenita de Oliveira, Marina Andrade Lima, Marina Buarque de Almeida, Rafael Stelmach, Paulo Márcio Pitrez & Alberto Cukier. (2020) 2020 Brazilian Thoracic Association recommendations for the management of asthma. Jornal Brasileiro de Pneumologia 46:1.
Crossref
Crossref
Susetta Finotto. (2019) Resolution of allergic asthma. Seminars in Immunopathology 41:6, pages 665-674.
Crossref
Crossref
Ravdeep Kaur & Geoffrey Chupp. (2019) Phenotypes and endotypes of adult asthma: Moving toward precision medicine. Journal of Allergy and Clinical Immunology 144:1, pages 1-12.
Crossref
Crossref